Neuropilin-1 (Nrp-1) contributes to maintaining the stability of CD4 CD25 regulatory T cells (T). We investigated the impact of Nrp-1 on the stability of CD4 CD25 T, and the underlying signaling pathways, in a model of sepsis. Splenic CD4 CD25 T were either treated with anti-Nrp-1, transfected to silence Nrp-1 and inhibitor of NF-κB kinase subunit beta (IKKβ), or administered ammonium pyrrolidine dithiocarbamate (PDTC), followed by recombinant semaphorin 3A (rSema3A), in a simulation of sepsis. After the creation of a sepsis model in mice, anti-Nrp-1 was administered. The expression of the gene encoding forkhead box protein P-3 foxp3-T-specific demethylated region (), the apoptosis rate, the expression of Foxp-3, cytotoxic T-lymphocyte-associated protein-4 (CTLA-4), and transforming growth factor β1 (TGF-β1), interleukin 10 (IL-10) and TGF-β1 secretion, and the NF-κB signaling activity of CD4 CD25 T were determined. Sepsis simulation with or without rSema3A increased the stability of CD4 CD25 T, including an increase in the expression of Foxp-3, CTLA-4, and TGF-β1, decreases in apoptosis and the methylation of , increases in the secretion of TGF-β1 and IL-10, and an increase in the immunosuppressive effect on CD4 T lymphocytes. Silencing of Nrp-1 or anti-Nrp-1 treatment abrogated lipopolysaccharide (LPS) stimulation with or without an rSema3A-mediated effect. Sepsis simulation increased the DNA-binding activity of NF-κB, as well as the ratios of phosphorylated IKKβ (p-IKKβ) to IKKβ and p-P65 to P65 and Silencing of IKKβ expression or PDTC treatment suppressed the stability of CD4 CD25 T in LPS-induced sepsis. Weakening Nrp-1 reduced the stability of CD4 CD25 T by regulating the NF-κB signaling pathway; thus, Nrp-1 could be a new target for immunoregulation in sepsis.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7822139 | PMC |
http://dx.doi.org/10.1128/IAI.00399-20 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!